Oncological treatment administration at end of life: a retrospective study.
Future Oncol
; 20(6): 329-334, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38420932
ABSTRACT
Background:
This work evaluated the proportion of patients who continue therapy until their last month of life or initiate a new therapy in the last 3 months of life (end of life [EOL]).Methods:
Data for 486 patients were retrospectively collected.Results:
In EOL, 205 (42.3%) received systemic therapy. Better performance status (last month overall response [OR] 0.39; 95% CI 0.25-0.60; p < 0.001; last 3 months OR 0.47; 95% CI 0.34-0.65; p < 0.001) and lack of activation of palliative care (last month OR 0.26; 95% CI 0.13-0.54; p < 0.001; last 3 months OR 0.18; 95% CI 0.10-0.32; p < 0.001) were associated with higher probability of EOL therapy.Conclusion:
A non-negligible proportion of patients in real-life settings continue to receive systemic treatment in EOL.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cuidado Terminal
/
Neoplasias
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article